Kieran Gallahue sold $268k of EW
director at Edwards Lifesciences Corp. 3,058 shares at an average of $87.61, traded Feb 23, 2024, filed Feb 26, 2024.
Score components
- +15RoleDirector
- +13Trade size$268k at market
- 0Share of holdings soldSold 4.4% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001225208-24-002963, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 23, 2024 | MOption exercise Common Stock | +7,056 | $36.86 | $260k | 10,757 | Feb 26, 2024 |
| Feb 23, 2024 | GGift Common Stock | -7,056 | $0.00 | $0 | 3,701 | Feb 26, 2024 |
| Feb 23, 2024 | GGift Common Stockindirect: By Trust | +7,056 | $0.00 | $0 | 70,277 | Feb 26, 2024 |
| Feb 23, 2024 | SOpen-market sale Common Stockindirect: By Trust | -3,058 | $87.61 | $268k | 67,219 | Feb 26, 2024 |
| Feb 23, 2024 | MOption exercise Director Stock Option (Right to Acquire)derivative | -7,056 | $0.00 | $0 | 0 | Feb 26, 2024 |
Related signals
Other insiders at Edwards Lifesciences Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $53k 619 shares | -2% | |
| 2Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $54k 619 shares | -2% | |
| 37Weak | Edwards Lifesciences Corp | Andrew M. Dahl SVP, Corporate Controller | $50k 544 shares | -4% | |
| 48Moderate | Edwards Lifesciences Corp | Annette Bruls CVP, EMEACLA | $238k 2,644 shares | -13% | |
| 50Moderate | Edwards Lifesciences Corp | Daveen Chopra CVP, TMTT, Surgical & IHFM | $2.9M 31,800 shares | -42% | |
| 40Moderate | Edwards Lifesciences Corp | Wayne Markowitz CVP, JAPAC | $113k 1,240 shares | -6% | |
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $57k 619 shares | -2% | |
| 30Weak | Edwards Lifesciences Corp | Wayne Markowitz CVP, JAPAC | $13k 146 shares | -1% | |
| 47Moderate | Edwards Lifesciences Corp | Wayne Markowitz CVP, JAPAC | $819k 9,628 shares | -31% | |
| 51Moderate | Edwards Lifesciences Corp | Bernard J Zovighian CEO | $245k 2,921 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.